How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

241 results for

Eslicarbazepine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

221. Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Group 1 BIA 2-093 + Oxcarbazepine Period 1 - Subjects recieved 900 mg of BIA 2-093 Period 2 - Subjects recieved 900 mg of oxcarbazepine Drug: BIA 2-093 Tablets containing BIA 2-093 in doses of 300 and 600 mg Other Name: Eslicarbazepine acetate Drug: Oxcarbazepine Tablets containing 300 mg and 600 mg of Trileptal® Other Name: Trileptal® Active Comparator: Group 2 Oxcarbazepine + BIA 2-093 Period 1 - Subjects (...) recieved 900 mg of oxcarbazepine Period 2 - Subjects recieved 900 mg of BIA 2-093 Drug: BIA 2-093 Tablets containing BIA 2-093 in doses of 300 and 600 mg Other Name: Eslicarbazepine acetate Drug: Oxcarbazepine Tablets containing 300 mg and 600 mg of Trileptal® Other Name: Trileptal® Outcome Measures Go to Primary Outcome Measures : Maximum Drug Concentration (Cmax) [ Time Frame: at pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72 and 96 hours post-dose ] Maximum observed plasma concentration

2012 Clinical Trials

222. The efficacy and tolerability of perampanel and other recently approved anti-epileptic drugs for the treatment of refractory partial onset seizure: a systematic review and Bayesian network meta-analysis. (PubMed)

The efficacy and tolerability of perampanel and other recently approved anti-epileptic drugs for the treatment of refractory partial onset seizure: a systematic review and Bayesian network meta-analysis. This paper compares the efficacy and tolerability of perampanel (PER) relative to other recently approved anti-epileptic drug (AEDs) - lacosamide (LCS), retigabine (RTG), and eslicarbazepine (ESL) for the adjunctive treatment of partial onset seizures with or without secondary generalization

2013 Current medical research and opinion

223. The Therapeutic Effects of Topiramate and Metformin on Second Generation Antipsychotics-induced Obesity

(Olanzapine, Clozapine, Quetiapine, Risperidone, Amisulpride, Zotepine) Exclusion Criteria: Allergy to metformin or topiramate Currently taking metformin or topiramate Currently taking drugs that may interact with topiramate, including carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, primidone, amitriptyline, lithium, metformin, propranolol, and sumatriptan. Being pregnant or planning to become pregnant during the study period, History of hypertension, DM, liver or renal function

2011 Clinical Trials

224. Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma

, oxcarbazepine, eslicarbazepine, rufinamide, and felbamate. Participant must be off any EIAEDs for at least two weeks prior to starting study drug. A list of EIAED and other inducers of CYP3A4 is provided in Table C-3 of Appendix C of the protocol. Participants taking a drug known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A (protoocol Appendix C). Participant must be off CYP3A inhibitors and inducers for at least two weeks prior to starting study drug. NOTE: participants must avoid

2011 Clinical Trials

225. eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam

is taking levetiracetam (LEV) in combination with 1 sodium channel blocking antiepileptic drug (defined as carbamazepine, lamotrigine, oxcarbazepine, phenytoin, or eslicarbazepine) as adjunctive treatment for epilepsy The minimum required seizure frequency during the 8-week Retrospective Seizure Baseline is on average ≥ 2 partial-onset seizures per 28 days with at least 1 seizure per 4 week period within the 8-week Retrospective Seizure Baseline. Additionally, subjects must experience at least 1 seizure

2011 Clinical Trials

226. Drugs in Pregnancy

(brivaracetam, eslicarbazepine ) are available; there is little to no information about their effects during pregnancy. ‡ The European Society for Medical Oncology (ESMO) has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. Generally, if chemotherapy is indicated, it should not be given during the1st trimester but may begin during the 2nd trimester; the last chemotherapy dose should be given ≥ 3 wk before anticipated delivery, and chemotherapy should not be given

2013 Merck Manual (19th Edition)

227. Drug Treatment of Seizures

tonic-clonic seizures Carbamazepine Lamotrigine Levetiracetam Oxcarbazepine Fosphenytoin Phenytoin Topiramate First-line monotherapy Divalproex Eslicarbazepine Gabapentin Lacosamide Perampanel Pregabalin Valproate Zonisamide 2nd-line monotherapy or adjunctive therapy Clobazam Felbamate Tiagabine Vigabatrin 3rd-line monotherapy or adjunctive therapy Phenobarbital Although effective, often considered less desirable because it is sedating and can cause behavioral problems in children Typical nonmotor (...) commonly used antiseizure drugs. Because hepatic side effects are possible, patients taking divalproex should have liver function tests every 3 mo for 1 yr; if serum transaminases or ammonia levels increase significantly (> 2 times the upper limit of normal), the drug should be stopped. An increase in ammonia up to 1.5 times the upper limit of normal can be tolerated safely. Eslicarbazepine Eslicarbazepine is indicated for treatment of focal-onset seizures as monotherapy or adjunctive therapy. Unlike

2013 Merck Manual (19th Edition)

228. Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications (Full text)

Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications In the past twenty years, 14 new antiepileptic drugs have been approved for use in the United States and/or Europe. These drugs are eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topiramate, vigabatrin and zonisamide. In general, the clinical utility of therapeutic drug monitoring has not been established in clinical trials

2010 Pharmaceuticals

229. Current and Emerging Therapies for the Management of Bipolar Disorders (Full text)

, carbamazepine, nearly all antipsychotics), acute bipolar depression (lamotrigine, quetiapine, olanzapine/fluoxetine combination), and relapse prevention (lithium, lamotrigine, divalproex, most second generation antipsychotics). There are also novel treatments that are being studied for all three phases. These include eslicarbazepine, cariprazine, MEM-1003, memantine, tamoxifen and pentazocine for acute mania; pramipexole, modafinil, armodafinil, divalproex, lurasidone, agomelatine, cariprazine

2011 Journal of central nervous system disease

230. Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy

Results First Posted : August 5, 2013 Last Update Posted : July 2, 2014 Sponsor: Bial - Portela C S.A. Information provided by (Responsible Party): Bial - Portela C S.A. Study Details Study Description Go to Brief Summary: The primary objective of the study is to evaluate the efficacy of eslicarbazepine acetate once-daily at doses of 400 mg, 800 mg and 1200 mg compared with placebo as adjunctive therapy in patients with refractory partial epilepsy over a 12-week maintenance period. Patients who (...) complete Part I may enter a 1-year open-label extension. Condition or disease Intervention/treatment Phase Partial Epilepsy Drug: eslicarbazepine acetate Drug: placebo Drug: ESL - Part II Phase 3 Detailed Description: Part I was a 22-week parallel-group, randomized, placebo-controlled period (8 weeks baseline, 2 weeks double-blind titration, and 12 weeks maintenance). After completing the baseline period, patients were randomized in a 1:1:1:1 ratio to 1 of the 3 ESL dose levels or to placebo. Part II

2009 Clinical Trials

231. Dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: randomized, open-label, crossover, single-centre study in healthy volunteers. (PubMed)

Dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: randomized, open-label, crossover, single-centre study in healthy volunteers. To investigate the dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate (ESL) in healthy volunteers.This was a randomized, three-way crossover, single-centre study in 18 healthy volunteers. Subjects received a single dose of oral ESL 800 mg following a standard meal (...) )) geometric means ratios (GMRs) of BIA 2-005, the enantiomeric mixture of the ESL active metabolite eslicarbazepine and its enantiomer R-licarbazepine. Bioequivalence was assumed when the 90% CI of the test/reference GMR fell within the bioequivalence acceptance interval (80.00, 125.00).Following a single dose of ESL 800 mg in the forms of two 400 mg tablets and one 800 mg tablet, the test/reference GMR (%) and 90% CI for C(max), AUC(t) and AUC(infinity) were 100.78% (93.91, 108.16), 100.37% (97.82

2008 Drugs in R&D Controlled trial quality: uncertain

232. Temporal Lobe Epilepsy

valproate should be considered if carbamazepine and lamotrigine are unsuitable or not tolerated. Adjunctive treatment: offer carbamazepine, clobazam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, sodium valproate or topiramate as adjunctive treatment if first-line treatments are ineffective or not tolerated. Other anti-epileptic drugs (AEDs) that may be considered by the tertiary epilepsy specialist are eslicarbazepine acetate, lacosamide, phenobarbital, phenytoin, pregabalin, tiagabine

2008 Mentor

233. Pill Questions - What to Ask When Starting the OCP.

with special needs. For information on guidelines surrounding prescribing for girls under the age of 16, see the separate article. Interactions [ , , ] There are many commonly used medications which can affect the efficacy of the pill: Antibacterials - enzyme inducers only - eg, rifampicin, rifabutin. Antidepressants - St John's wort (which can be bought over-the-counter). Anticonvulsants - carbamazepine, oxcarbazepine, eslicarbazepine, phenobarbital, phenytoin, primidone and topiramate due to their enzyme

2008 Mentor

234. Contraception and Special Groups

: rifampicin and rifabutin. Anti-epileptics: carbamazepine, eslicarbazepine, phenytoin, phenobarbital, primidone, oxcarbazepine, topiramate. Central nervous system stimulant: modafinil. Antiretroviral drugs: nelfinavir, nevirapine, ritonavir. St John's wort. Combined hormonal contraception COC pill - all women should be advised to switch to a contraceptive method unaffected by enzyme inducers (eg, progestogen-only injectable, copper intrauterine device (Cu-IUCD) or LNG-IUS). Rifampicin and rifabutin

2008 Mentor

235. Combined Oral Contraceptive (Follow-up and Common Problems)

to show any evidence that significant weight gain is a side-effect of the pill. [ ] Interactions [ , , ] There are many commonly used medications which can affect the efficacy of the pill: Antibacterials - enzyme inducers only (eg, rifampicin, rifabutin). Antidepressants - St John's wort (which can be bought over-the-counter). Anticonvulsants - carbamazepine, oxcarbazepine, eslicarbazepine, phenobarbital, phenytoin, primidone and topiramate, due to their enzyme-inducing activity. Also lamotrigine

2008 Mentor

236. Anticonvulsants used for Partial Seizures

, levetiracetam, oxcarbazepine, sodium valproate, perampanel or topiramate as adjunctive treatment if first-line treatments are ineffective or not tolerated. Other AEDs that may be considered by the tertiary epilepsy specialist are eslicarbazepine acetate, lacosamide, phenobarbital, phenytoin, pregabalin, tiagabine, vigabatrin and zonisamide. NB : carefully consider the risk:benefit ratio when using vigabatrin because of the risk of an irreversible effect on visual fields. Interactions [ ] Interactions

2008 Mentor

237. Anticonvulsants used for Generalised Seizures

are eslicarbazepine acetate, lacosamide, phenobarbital, phenytoin, pregabalin, tiagabine, vigabatrin and zonisamide. Idiopathic generalised epilepsy (IGE) First-line treatment: offer sodium valproate as first-line treatment, particularly if there is a photo-paroxysmal response on EEG. Offer lamotrigine if sodium valproate is unsuitable or not tolerated. Lamotrigine can exacerbate myoclonic seizures. Consider topiramate but it has a less favourable side-effect profile than sodium valproate and lamotrigine

2008 Mentor

238. Therapeutic Drug Monitoring

. There are several categories of drugs that require monitoring, as summarised here. Drug Category Drugs Treatment Use Cardiac drugs , digitoxin, amiodarone , , Antibiotics Aminoglycosides (gentamicin, tobramycin, amikacin, , chloramphenicol) Infections with bacteria that are resistant to less powerful antibiotics Antiepileptics , , , , (rarely: ethosuximide, gabapentin, lamotrigine, levetiracetam, topiramate, zonisamide, eslicarbazepine, felbamate, lacosamide, oxcarbazepine, pregabalin, rufinamide, stiripentol

2004 Lab Tests Online UK

239. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. (Full text)

Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. To explore the efficacy and safety of eslicarbazepine acetate (BIA 2-093), a new antiepileptic drug, as adjunctive therapy in adult patients with partial epilepsy.A multicenter, double-blind, randomized, placebo-controlled study was conducted in 143 refractory patients aged 18-65 years with >or=4 partial-onset seizures/month. The study consisted of a 12-week (...) treatment period followed by a 1-week tapering off. Patients were randomly assigned to one of three groups: treatment with eslicarbazepine acetate once daily (QD, n=50), twice daily (BID, n=46), or placebo (PL, n=47). The daily dose was titrated from 400 mg to 800 mg and to 1,200 mg at 4-week intervals. The proportion of responders (patients with a >or=50% seizure reduction) was the primary end point.The percentage of responders versus baseline showed a statistically significant difference between QD

2007 Epilepsia Controlled trial quality: predicted high

240. Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). (PubMed)

Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). To investigate the effect of food on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel antagonist.Single-centre, open-label, randomised, two-way crossover study in 12 healthy subjects. The study consisted of two consecutive treatment periods separated by a washout of 14 days or more. In each of the study periods subjects were administered a single dose (...) of eslicarbazepine acetate 800 mg following either a standard high-fat content meal or 10 hours of fasting.Eslicarbazepine acetate was rapidly and extensively metabolised to BIA 2-005. Maximum BIA 2-005 plasma concentrations (C(max)) in fed (test) and fasting (reference) conditions were, respectively, 12.8 +/- 1.8 microg/mL and 11.3 +/- 1.9 microg/mL, and the areas under the plasma concentration time curve from 0 to infinity (AUC(infinity)) were, respectively, 242.5 +/- 32.1 microg.h/mL and 243.6 +/- 31.1

2005 Drugs in R&D Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>